Genmab stock has been reported to be under pressure, with several notable events affecting its performance. The company made a massive $1.8 Billion acquisition of
ProfoundBio, a developer of Ovarian Cancer drugs. It also embarked on a multi-billion share buy-back program, which elicited mixed reactions from shareholders. Various institutional investors have been adjusting their stake in the company, with notable organizations like
Neuberger Berman Group LLC and
Vanguard Personalized Indexing Management LLC reducing their shares, while others like
Assetmark Inc.,
PNC Financial Services Group Inc., and
Envestnet Portfolio Solutions Inc. increased theirs. The company's recent Q1 2024 earnings showed a significant increase of 46% compared to last year and beat earnings per share (EPS) and revenue estimates. Still, despite the strong financials, the stock took a dip to $29.34, sparking fears amongst investors. Finally, it's worth noting some developments such as the completion of share buy-back programs, the reaffirmation of stock ratings by HC Wainwright and some ongoing controversy concerning the company's CEO compensation package.
Genmab Stocks News Analytics from Fri, 14 Aug 2015 07:00:00 GMT to Wed, 29 May 2024 11:57:40 GMT -
Rating -3
- Innovation -4
- Information 6
- Rumor -5
